^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tice BCG (live attenuated bacillus Calmette-Guerin)

    i
    Other names: BCG vaccine
    Associations

    News

    Trials
    Company:
    Merck (MSD), Texas A&M University
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    4ms
    Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST) (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, University of Virginia
    New P2 trial
    |
    Tice BCG (live attenuated bacillus Calmette-Guerin)
    7ms
    In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • docetaxel • Jelmyto (mitomycin urothelial gel) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    8ms
    S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=1000, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Sep 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Tice BCG (live attenuated bacillus Calmette-Guerin)
    10ms
    EVER: Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients with Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (clinicaltrials.gov)
    P3, N=540, Recruiting, Verity Pharmaceuticals Inc. | Not yet recruiting --> Recruiting | Trial completion date: Jan 2026 --> Feb 2029 | Trial primary completion date: Dec 2025 --> Feb 2029
    Enrollment open • Trial completion date • Trial primary completion date • Head-to-Head
    |
    Tice BCG (live attenuated bacillus Calmette-Guerin)
    10ms
    ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, ImmunityBio, Inc.
    New P1/2 trial
    |
    Tice BCG (live attenuated bacillus Calmette-Guerin)
    12ms
    Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) (clinicaltrials.gov)
    P3, N=1397, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2028 --> Nov 2034
    Trial completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    12ms
    ALBAN: Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (clinicaltrials.gov)
    P3, N=517, Active, not recruiting, UNICANCER | Trial primary completion date: Oct 2024 --> Jun 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    1year
    S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=1000, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Feb 2025 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    Tice BCG (live attenuated bacillus Calmette-Guerin)
    1year
    In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, Mayo Clinic
    New P1/2 trial
    |
    gemcitabine • docetaxel • Jelmyto (mitomycin urothelial gel) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    1year
    Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) (clinicaltrials.gov)
    P3, N=1397, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    Keytruda (pembrolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    1year
    ALBAN: Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (clinicaltrials.gov)
    P3, N=516, Active, not recruiting, UNICANCER | Trial completion date: Feb 2028 --> Oct 2028 | Trial primary completion date: Apr 2024 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    over1year
    NU 15U06: Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
    P1, N=9, Completed, Northwestern University | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    Keytruda (pembrolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)